AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16506965 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% rapeseed oil (RO)
Number of subjects: 58
Study 16506965 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% fish oil / 50% rapeseed oil (FO/RO)
Number of subjects: 58
Study 16506965 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study 12949360 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 isoenergetic meals every 4 hours (N-eat)
Number of subjects: 7
Study 12949360 — intervention group
Group type: COMPARATOR
Intervention: 4 isoenergetic meals from 0800 to 2000 h followed by a nocturnal fast (N-fast)
Number of subjects: 7
Study 12949360 — intervention group
Group type: COMPARATOR
Intervention: N-fast
Number of subjects: 7
Study 12949360 — intervention group
Group type: EXPERIMENTAL
Intervention: N-eat
Number of subjects: 7
Study 10896700 — intervention group
Group type: COMPARATOR
Intervention: Melancholic patients with no reduction in external cues
Number of subjects: 48
Study 10896700 — intervention group
Group type: COMPARATOR
Intervention: Melancholic patients with moderate reduction in external cues
Number of subjects: 48
Study 10896700 — intervention group
Group type: COMPARATOR
Intervention: Melancholic patients with high reduction in external cues
Number of subjects: 48
Study 10896700 — intervention group
Group type: COMPARATOR
Intervention: Non-melancholic patients with high reduction in external cues
Number of subjects: 48
Study 10896700 — intervention group
Group type: COMPARATOR
Intervention: Controls with high reduction in external cues
Number of subjects: 48
Study 8884424 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% VO2peak exercise
Number of subjects: 15
Study 8884424 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% VO2peak exercise
Number of subjects: 15
Study 8884424 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% VO2peak exercise
Number of subjects: 15
Study 1543816 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-galactosidase from Aspergillus niger added to intact milk
Number of subjects: 16
Study 3717533 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise challenge tests (standardized protocol)
Number of subjects: 58
Study 31327162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 60
Study 31327162 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 60
Study 31327162 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 30093522 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial evaluation by a physical therapist (PT) integrated into primary care
Number of subjects: 0
Study 30093522 — intervention group
Group type: COMPARATOR
Intervention: Usual evaluation by a primary care provider (PCP)
Number of subjects: 0
Study 27876689 — intervention group
Group type: EXPERIMENTAL
Intervention: SESAMe software (Web-based app for scheduling and monitoring emails)
Number of subjects: 270
Study 24276460 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib 50 mg once weekly
Number of subjects: 44
Study 24276460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23656642 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusions
Number of subjects: 600
Study 23656642 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic platelet transfusions
Number of subjects: 600
Study 19900820 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1beta (IL-1beta) concentration in HbSS-NS (n=13)
Number of subjects: 39
Study 19900820 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1beta (IL-1beta) concentration in HbSS-S (n=13)
Number of subjects: 39
Study 19900820 — intervention group
Group type: COMPARATOR
Intervention: HbSS steady-state controls (n=7)
Number of subjects: 39
Study 19900820 — intervention group
Group type: COMPARATOR
Intervention: HbAA controls (n=6)
Number of subjects: 39
Study 18097230 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz, zidovudine plus lamivudine
Number of subjects: 1266
Study 18097230 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz plus indinavir
Number of subjects: 1266
Study 18097230 — intervention group
Group type: COMPARATOR
Intervention: indinavir, zidovudine plus lamivudine
Number of subjects: 1266
Study 18097230 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz, zidovudine plus lamivudine and indinavir, zidovudine, lamivudine
Number of subjects: 1266
Study 19158582 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic hospital order referral
Number of subjects: 184
Study 19158582 — intervention group
Group type: COMPARATOR
Intervention: Screening ineligibility due to provider-oriented reasons
Number of subjects: 184
Study 19158582 — intervention group
Group type: COMPARATOR
Intervention: Screening ineligibility due to patient-oriented factors
Number of subjects: 184
Study 19158582 — intervention group
Group type: COMPARATOR
Intervention: Screening ineligibility linked to study protocol
Number of subjects: 184
Study 19158582 — intervention group
Group type: COMPARATOR
Intervention: Study nonparticipation of those eligible
Number of subjects: 184
Study 15688961 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush with antimicrobial additive (Microban)
Number of subjects: 20
Study 15688961 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush without antimicrobial agent (control)
Number of subjects: 20
Study 11819790 — intervention group
Group type: EXPERIMENTAL
Intervention: supplemented diet with glutamine, arginine and omega‐3‐fatty acids
Number of subjects: 48
Study 11819790 — intervention group
Group type: COMPARATOR
Intervention: standard diet
Number of subjects: 48
Study 9567620 — intervention group
Group type: EXPERIMENTAL
Intervention: Rokitamycin 800 mg/day
Number of subjects: 20
Study 9567620 — intervention group
Group type: EXPERIMENTAL
Intervention: Rokitamycin 1200 mg/day
Number of subjects: 20
Study 7947364 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (4 mg/day)
Number of subjects: 26
Study 7947364 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (10 mg/day)
Number of subjects: 26
Study 7947364 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin and Nitrendipine
Number of subjects: 26
Study 3360340 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection to the antagonist, nonparalytic horizontal rectus muscle
Number of subjects: 43
Study 3360340 — intervention group
Group type: COMPARATOR
Intervention: Control group (no botulinum toxin treatment)
Number of subjects: 43
Study 31958877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pills (COCP) containing 20 mcg ethinyl estradiol/150 mg desogestrel for two continuous cycles
Number of subjects: 84
Study 31958877 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (NSAID); mefenamic acid 500 mg TDS for 5 days, 21 days apart for two cycles
Number of subjects: 84
Study 31002478 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-hour time-restricted feeding early (TRFe)
Number of subjects: 15
Study 31002478 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-hour time-restricted feeding delayed (TRFd)
Number of subjects: 15
Study 31002478 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-hour time-restricted feeding (TRF)
Number of subjects: 15
Study 27871076 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for 1 week pre-URS
Number of subjects: 165
Study 25637076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 67
Study 25637076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 25632646 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin 200 sg/kg body weight
Number of subjects: 148
Study 25632646 — intervention group
Group type: COMPARATOR
Intervention: Topical lindane lotion 1% (two applications with a 1-week interval)
Number of subjects: 148
Study 21511828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 1200 mg/d
Number of subjects: 77
Study 21511828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 21511828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 2400 mg/d
Number of subjects: 77
Study 19643495 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg intravitreal ranibizumab
Number of subjects: 4300
Study 19643495 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intravitreal ranibizumab
Number of subjects: 4300
Study 17370044 — intervention group
Group type: EXPERIMENTAL
Intervention: Carers with low mood
Number of subjects: 82
Study 17370044 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepant views about illness consequences
Number of subjects: 82
Study 17370044 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepant views on controllability
Number of subjects: 82
Study 17370044 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness perceptions
Number of subjects: 82
Study 15243609 — intervention group
Group type: EXPERIMENTAL
Intervention: Local haemostasis using oxidised regenerated cellulose after gauze packing for 3 minutes
Number of subjects: 25
Study 15243609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no local haemostasis)
Number of subjects: 25
Study 11376178 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 174
Study 11376178 — intervention group
Group type: COMPARATOR
Intervention: Non-Hormone Replacement Therapy (non-HRT)
Number of subjects: 174
Study 11376178 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 174
Study 9338666 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autograft
Number of subjects: 157
Study 9338666 — intervention group
Group type: COMPARATOR
Intervention: Bare sclera excision
Number of subjects: 157
Study 8177385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group (cooled to 32 to 33 degrees C within 6 hours of injury, n = 20)
Number of subjects: 36
Study 8177385 — intervention group
Group type: COMPARATOR
Intervention: Normothermic group (n = 16)
Number of subjects: 36
Study 8177385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group
Number of subjects: 36
Study 8177385 — intervention group
Group type: COMPARATOR
Intervention: Normothermic group
Number of subjects: 36
Study 3429382 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 0
Study 3429382 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 0
Study 3429382 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0
Study 3429382 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic)
Number of subjects: 0
Study 31826235 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT volume and 18F‐FDG uptake after personalized cold exposure
Number of subjects: 102
Study 31826235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean mass
Number of subjects: 102
Study 31826235 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT volume and BAT 18F‐FDG uptake
Number of subjects: 102
Study 29531100 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma APGAR tools
Number of subjects: 1066
Study 29531100 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1066
Study 27016338 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic augmented feedback during spinal manipulation training
Number of subjects: 40
Study 27016338 — intervention group
Group type: COMPARATOR
Intervention: Progressive withdrawal of augmented feedback during spinal manipulation training (Control group)
Number of subjects: 40
Study 24814553 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 82
Study 23098348 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of causes of heart failure in hypertensive patients
Number of subjects: 194
Study 23098348 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of left ventricular hypertrophy as a risk factor
Number of subjects: 194
Study 23098348 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of major mechanisms of heart failure in hypertension
Number of subjects: 194
Study 20533545 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (∼10 mg/kg of body weight)
Number of subjects: 175
Study 20533545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 20533545 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 175
Study 18793927 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cone with quartz‐tungsten‐halogen (QTH) curing
Number of subjects: 120
Study 18793927 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cone with light‐emitting diode (LED) curing
Number of subjects: 120
Study 18793927 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cone with plasma‐arc curing (PAC)
Number of subjects: 120
Study 18793927 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cone with chemical cure (uncured)
Number of subjects: 120
Study 18793927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with quartz‐tungsten‐halogen (QTH) curing
Number of subjects: 120
Study 18793927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with light‐emitting diode (LED) curing
Number of subjects: 120
Study 18793927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with plasma‐arc curing (PAC)
Number of subjects: 120
Study 18793927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with chemical cure (uncured)
Number of subjects: 120
Study 18793927 — intervention group
Group type: EXPERIMENTAL
Intervention: System B + Obtura with quartz‐tungsten‐halogen (QTH) curing
Number of subjects: 120
Study 18793927 — intervention group
Group type: EXPERIMENTAL
Intervention: System B + Obtura with light‐emitting diode (LED) curing
Number of subjects: 120
Study 18793927 — intervention group
Group type: EXPERIMENTAL
Intervention: System B + Obtura with plasma‐arc curing (PAC)
Number of subjects: 120
Study 18793927 — intervention group
Group type: EXPERIMENTAL
Intervention: System B + Obtura with chemical cure (uncured)
Number of subjects: 120
Study 16459896 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic lexical decision task (positive response for words)
Number of subjects: 32
Study 16459896 — intervention group
Group type: COMPARATOR
Intervention: Modified lexical decision task (no response to words)
Number of subjects: 32
Study 11953343 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori
Number of subjects: 0
Study 11953343 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9477021 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (scaling and rootplaning of all pockets in 2 visits within 24 h, tongue brushing with 1% chlorhexidine gel for 1 min, mouth rinsing with 0.2% chlorhexidine solution for 2 min, subgingival irrigation of all pockets with 1% chlorhexidine gel 3x in 10 min, rinsing 2x daily with 0.2% chlorhexidine, spraying tonsils with 0.2% chlorhexidine for 2 months)
Number of subjects: 16
Study 9477021 — intervention group
Group type: COMPARATOR
Intervention: Control group (scaling and rootplaning per quadrant at 2-week intervals, oral hygiene instructions)
Number of subjects: 16
Study 7627417 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin protectant products (12 products evaluated)
Number of subjects: 0
Study 2667780 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA)
Number of subjects: 44
Study 2667780 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anaesthesia (SA) with sedation
Number of subjects: 44
Study 2667780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study 799557 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 0
Study 799557 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0
Study 799557 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study 28735449 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 28735449 — intervention group
Group type: COMPARATOR
Intervention: Colloid bismuth subcitrate
Number of subjects: 0
Study 27606616 — intervention group
Group type: EXPERIMENTAL
Intervention: Körpertambura treatment (10-minute session)
Number of subjects: 54
Study 27606616 — intervention group
Group type: COMPARATOR
Intervention: Active control group (Atemtherapie)
Number of subjects: 54
Study 24955356 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaffold enriched with autologous bone marrow stem cells (ABMC) (Group A)
Number of subjects: 30
Study 24955356 — intervention group
Group type: COMPARATOR
Intervention: Fracture fixation alone (Group B)
Number of subjects: 30
Study 22776216 — intervention group
Group type: EXPERIMENTAL
Intervention: TdaP vaccine
Number of subjects: 802
Study 22776216 — intervention group
Group type: COMPARATOR
Intervention: Td vaccine
Number of subjects: 802
Study 20479425 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CIS) 100 mg/m(2) on day 1 of weeks 1, 4, and 7
Number of subjects: 861
Study 20479425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CIS) 75 mg/m(2) plus Tirapazamine (TPZ) 290 mg/m(2)/d on day 1 of weeks 1, 4, and 7 and TPZ alone 160 mg/m(2)/d on days 1, 3, and 5 of weeks 2 and 3 (TPZ/CIS)
Number of subjects: 861
Study 20479425 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CIS)
Number of subjects: 861
Study 18410547 — intervention group
Group type: EXPERIMENTAL
Intervention: LT4-LT3 combination therapy
Number of subjects: 141
Study 18410547 — intervention group
Group type: COMPARATOR
Intervention: LT4 monotherapy
Number of subjects: 141
Study 15634723 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin-B and folic acid therapy (n = 27)
Number of subjects: 49
Study 15634723 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 49
Study 15634723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 12879814 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiron (local formulation of risperidone)
Number of subjects: 12
Study 12879814 — intervention group
Group type: COMPARATOR
Intervention: Risperdal (original formulation of risperidone)
Number of subjects: 12
Study 11709253 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% applied 2 hours before surgery
Number of subjects: 64
Study 11709253 — intervention group
Group type: COMPARATOR
Intervention: Control (no latanoprost)
Number of subjects: 64
Study 9169310 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 302
Study 9169310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 302
Study 9169310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 8256322 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 105
Study 8256322 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 105
Study 3875450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg/day
Number of subjects: 12
Study 3875450 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg/day
Number of subjects: 12
Study 3875450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29358002 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural food based tube feeding
Number of subjects: 118
Study 29358002 — intervention group
Group type: COMPARATOR
Intervention: Standard tube feeding
Number of subjects: 118
Study 28332859 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (2 mL) in 2 mL normal saline
Number of subjects: 100
Study 28332859 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (4 mL)
Number of subjects: 100
Study 27713626 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (95% of estimated VO2 max)
Number of subjects: 31
Study 27713626 — intervention group
Group type: COMPARATOR
Intervention: Regular intensity exercise (85% of estimated VO2 max)
Number of subjects: 31
Study 27713626 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 31
Study 27713626 — intervention group
Group type: COMPARATOR
Intervention: Regular intensity exercise
Number of subjects: 31
Study 23965288 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental Disability-Child Global Assessment Scale
Number of subjects: 30
Study 22957434 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic pump tablets with EC/PVP K30
Number of subjects: 0
Study 22957434 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 0
Study 20732978 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the Canadian CT Head Rule with active strategies including education, policy changes, and real-time reminders.
Number of subjects: 4531
Study 20732978 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no intervention).
Number of subjects: 4531
Study 17564561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin-C
Number of subjects: 70
Study 17564561 — intervention group
Group type: COMPARATOR
Intervention: Creatinine
Number of subjects: 70
Study 17564561 — intervention group
Group type: COMPARATOR
Intervention: Cockcroft-Gault (C-G)
Number of subjects: 70
Study 17564561 — intervention group
Group type: COMPARATOR
Intervention: MDRD
Number of subjects: 70
Study 16211699 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD diagnosis through endoscopy and symptoms assessment
Number of subjects: 2760
Study 16211699 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosive esophagitis diagnosis through endoscopy
Number of subjects: 2760
Study 16211699 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic GERD diagnosis based on QUEST score
Number of subjects: 2760
Study 16211699 — intervention group
Group type: EXPERIMENTAL
Intervention: NERD diagnosis from symptomatic GERD
Number of subjects: 2760
Study 16211699 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors for erosive esophagitis
Number of subjects: 2760
Study 16211699 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factor for GERD symptoms
Number of subjects: 2760
Study 16211699 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of traditional Japanese foods on GERD symptoms
Number of subjects: 2760
Study 11489017 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery of Stress Instrument (MSI)
Number of subjects: 0